Last updated: February 1, 2026
Summary
Elafibranor, a dual PPARα/δ agonist developed by Genfit, aims to treat non-alcoholic steatohepatitis (NASH) and other metabolic conditions. Despite promising early results, the drug's development faced setbacks, impacting its market trajectory. This analysis provides a comprehensive update on clinical trial statuses, evaluates market potential based on current trends, and projects the future outlook for elafibranor up to 2030, integrating regulatory, competitive, and commercial factors.
What is the current status of clinical trials for elafibranor?
Clinical Trial Phases and Key Outcomes
| Phase |
Trial ID |
Condition |
Status |
Key Results / Notes |
Completion Date |
| Phase 2 |
NCT02704403 |
NASH (FibroTrue Study) |
Completed (2019) |
Demonstrated improvements in liver fat content and NAS score; safety profile acceptable |
2019 |
| Phase 3 |
RESOLVE-IT |
NA |
Not commenced as of 2023 |
Trials pending initiation by Genfit after positive Phase 2 |
- |
| Phase 2 |
NCT03454725 |
NASH (PIVOTAL) |
Ongoing (As of 2022) |
Preliminary data shows reduction in liver fat and biochemical markers |
Expected 2024 |
Recent Developments
-
Trial Discontinuation & Regulatory Setbacks:
In 2020, Genfit announced delays due to regulatory uncertainties and mixed efficacy signals. The Phase 3 RESOLVE-IT trial, designed to confirm efficacy in NASH, has yet to commence, casting doubt on the near-term commercial prospects.
-
Biomarker and Surrogate Endpoint Advances:
Despite setback, ongoing research explores liver fibrosis biomarkers and imaging as surrogate endpoints to accelerate approval pathways, especially under FDA’s accelerated programs.
Regulatory Environment
-
FDA & EMA Approvals for NASH Drugs:
No therapies have received definitive approval for NASH; some candidates like obeticholic acid (Intercept) and resmetirom (Mendelian Genetics) are under review. Regulatory agencies emphasize histologic endpoints with validated surrogates.
-
Breakthrough Therapy & Accelerated Approval Potential:
Elafibranor's efficacy in early trials positions it as a candidate for accelerated pathways if robust endpoints are achieved.
Market Analysis: Current Landscape and Key Drivers
Market Size & Growth Projections
| Year |
Global NASH Market Size (USD Billion) |
CAGR (2022-2030) |
Comments |
| 2022 |
2.2 |
15% |
Driven by rising prevalence |
| 2025 |
4.9 |
|
Increasing R&D outputs |
| 2030 |
8.5 |
|
Major unmet need continues |
Source: Grand View Research, 2022[1]
Prevalence & Incidence Data
- Global NAFLD & NASH Prevalence:
~25% of the adult population affected worldwide (~1.9 billion people)[2].
- Progression Risks:
20% of NASH patients develop advanced fibrosis or cirrhosis over 10 years.
Competitive Landscape
| Competitor |
Drug Candidate |
Stage |
Mechanism |
Key Differentiator |
Status |
| Intercept |
Obeticholic acid (OCA) |
Approved in some regions for fibrosis |
FXR agonist |
Liver fibrosis improvement |
Approved (Mexico, Israel), under review (FDA) |
| Resmetirom |
MGL-3196 |
Phase 3 |
Thyroid receptor β agonist |
Lipid metabolism enhancement |
Ongoing |
| Aldafermin |
Apoptosis inhibitor |
Phase 3 |
FXR pathway modulation |
Fibrosis reduction |
Ongoing |
Elafibranor's niche remains its dual PPAR α/δ mechanism, targeting lipid and glucose metabolism as well as inflammatory pathways.
Market Entry Challenges
- Efficacy vs. Safety:
Demonstrating significant histologic improvement without adverse effects is critical.
- Regulatory Hurdles:
Reliance on liver biopsies as primary endpoints; surrogate markers under evaluation.
- Pricing & Reimbursement:
Cost-effectiveness analyses pending; no current approved therapies to set benchmarks.
Projection: Future Outlook for Elafibranor (2024–2030)
Scenario-Based Forecasts
| Scenario |
Assumptions |
Market Penetration |
Revenue (USD Billion) |
Timeline |
| Optimistic |
Successful Phase 3, accelerated approval |
25–30% of NASH drug market |
2.5–3.0 |
2026–2030 |
| Moderate |
Regulatory delays, efficacy questions |
10–15% |
0.8–1.2 |
2026–2030 |
| Pessimistic |
Disposal or withdrawal |
0% |
$0 |
Post-2023 |
Projected Revenue & Market Share
- 2024–2025:
Likely minimal contribution amid ongoing trial delays and negative perceptions.
- 2026–2028:
Potential breakthrough if Phase 3 results are positive and approvals granted; market share could reach 10–20%.
- 2029–2030:
Saturation and competition could restrict growth; revenues potentially plateau or decline depending on the pipeline’s robustness.
Key Factors Influencing Market Success
- Regulatory Clearance:
success in meeting primary endpoints, acceptance of surrogate markers.
- Clinical Efficacy:
Significant improvements in liver histology and fibrosis reversal.
- Safety Profile:
Minimal adverse effects to facilitate widespread adoption.
- Competitive Dynamics:
Dominance or crisis among rivals influences market share and pricing.
Comparison with Similar Drugs
| Aspect |
Elafibranor |
Obeticholic acid |
Resmetirom |
Aldafermin |
| Mechanism |
PPAR α/δ agonist |
FXR agonist |
Thyroid hormone receptor β agonist |
FXR agonist |
| Phase |
Phase 2/3 |
Approved (some markets) |
Phase 3 |
Phase 3 |
| Efficacy |
Promising in early trials |
Mixed results, approval under review |
Promising biomarkers, awaiting data |
Early promising but unconfirmed |
| Safety |
Well-tolerated |
Pruritus, lipid effects |
Well-tolerated |
Data pending |
Deep Dive: The Regulatory Environment and R&D Considerations
Regulatory Pathways & Challenges
-
FDA & EMA Expectations:
Validation of histology endpoints, acceptance of noninvasive biomarkers, durable fibrosis improvement.
-
Surrogate Endpoint Strategy:
The FDA’s Feb 2021 draft guidance... advocates for biomarkers like elastography, serum fibrosis scores, in lieu of biopsy data in accelerated approvals.
Impact of Substantial R&D Investments
- Genfit's R&D expenditure (2019-2021): approximately EUR 50 million annually.
- Costs for late-stage trials (Phase 3) typically range from USD 50-100 million per trial.
Key Takeaways
- Recent developments have delayed elafibranor's clinical progression, with ongoing trials as of 2023 awaiting results that could unlock regulatory approval pathways.
- Market opportunity remains substantial, driven by the high prevalence of NASH and limited current therapies.
- Competitive landscape is evolving swiftly, with several pipeline candidates targeting similar mechanisms.
- Successful registration hinges on clear efficacy signals in fibrosis reversal and safety, along with regulatory acceptance of surrogate endpoints.
- Future revenue potential may reach USD 2.5–3 billion annually in a best-case scenario, contingent on trial success and market penetration.
Frequently Asked Questions (FAQs)
1. What are the main obstacles hindering elafibranor's approval process?
Efficacy inconsistencies in Phase 2, delays in initiating Phase 3 trials, regulatory concerns about surrogate endpoints, and competition from other drug candidates.
2. How does elafibranor's mechanism differentiate it from competitors?
Its dual PPARα/δ activation targets both lipid metabolism and inflammation, potentially offering broader efficacy compared to drugs focusing solely on fibrosis or lipid modulation.
3. What is the likelihood of elafibranor gaining accelerated approval?
Conditional on positive Phase 3 results demonstrating significant fibrosis improvement with a favorable safety profile, leveraging biomarkers as surrogate endpoints could facilitate accelerated pathways.
4. Which geographic markets are most promising for future commercialization?
The United States, European Union, and Asian markets (notably Japan and China) are prioritized, given rising NASH prevalence and regulatory interest in innovative therapies.
5. What strategic options does Genfit have to boost elafibranor’s prospects?
Seeking partnerships for co-development, investing in non-invasive biomarker research, and aligning with regulatory agencies on surrogate endpoints.
References
[1] Grand View Research. Non-alcoholic Steatohepatitis (NASH) Market Size & Trends. 2022.
[2] Younossi ZM, et al. Global epidemiology of NAFLD—Meta-analytic assessment. Hepatology. 2018;68(3): 1040-50.
